Blog
About

7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trazodone effects on [ 3H]-paroxetine and α 2-adrenoreceptors in platelets of patients with major depression

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Trazodone is an antidepressant which behaves as a selective 5-HT 2 antagonist and 5-HT reuptake inhibitor. The lack of information on its effects in vivo prompted us to evaluate α 2-adrenoceptors by means of the specific binding of [ 3H]-rauwolscine, and the 5-HT transporter (SERT) by means of the binding of [ 3H]-paroxetine ([ 3H]-Par), in platelets of depressed patients, before and after one month of treatment with trazodone (75–300 mg/day). Twenty-five outpatients of both sexes with a diagnosis of major depression, as assessed by the Structured Clinical Interview for DSM IV, were included in the study. Depressive symptoms were evaluated by means of the Hamilton Rating Scale for Depression: the total score (mean ± SD) was 20 ± 6 at baseline (t 0) and 7 ± 4 after one month of treatment (t 1). Platelet membranes, [ 3H]- rauwolscine and [ 3H]-Par bindings were carried out according to standardized protocols. The results showed that the B max values of [ 3H]-Par were statistically lower at t 1 than at t 0 (733 ± 30 vs 1471 ± 99, P < 0.001), while the K d and the [ 3H]-rauwolscine binding parameters remained unchanged. The findings of this study suggest that in vivo trazodone modifies the number of the SERT proteins and that, perhaps, most of its antidepressant properties are related to this activity.

          Related collections

          Author and article information

          Journal
          Neuropsychiatr Dis Treat
          Neuropsychiatric Disease and Treatment
          Neuropsychiatric Disease and Treatment
          Dove Medical Press
          1176-6328
          1178-2021
          25 May 2010
          2010
          2010
          : 6
          : 255-259
          Affiliations
          Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Pisa, Italy
          Author notes
          Correspondence: Donatella Marazziti, Dipartimento di Psichiatria, Neurobiologia, Farmacologia, e Biotecnologie, University of Pisa, Via Roma 67, 56100 Pisa, Italy, Tel +39 050 835412, Fax +39 050 21581, Email dmarazzi@ 123456psico.med.unipi.it
          Article
          ndt-6-255
          2877607
          20520789
          © 2010 Marazziti et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Original Research

          Comments

          Comment on this article